Literature DB >> 23814161

Personalized medicine: does the molecular suit fit?

Edison T Liu1, Patrick G Johnston.   

Abstract

Mesh:

Year:  2013        PMID: 23814161      PMCID: PMC4063388          DOI: 10.1634/theoncologist.2013-0191

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


× No keyword cloud information.
  9 in total

1.  Delivering affordable cancer care in high-income countries.

Authors:  Richard Sullivan; Jeffrey Peppercorn; Karol Sikora; John Zalcberg; Neal J Meropol; Eitan Amir; David Khayat; Peter Boyle; Philippe Autier; Ian F Tannock; Tito Fojo; Jim Siderov; Steve Williamson; Silvia Camporesi; J Gordon McVie; Arnie D Purushotham; Peter Naredi; Alexander Eggermont; Murray F Brennan; Michael L Steinberg; Mark De Ridder; Susan A McCloskey; Dirk Verellen; Terence Roberts; Guy Storme; Rodney J Hicks; Peter J Ell; Bradford R Hirsch; David P Carbone; Kevin A Schulman; Paul Catchpole; David Taylor; Jan Geissler; Nancy G Brinker; David Meltzer; David Kerr; Matti Aapro
Journal:  Lancet Oncol       Date:  2011-09       Impact factor: 41.316

2.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Authors:  Eunice L Kwak; Yung-Jue Bang; D Ross Camidge; Alice T Shaw; Benjamin Solomon; Robert G Maki; Sai-Hong I Ou; Bruce J Dezube; Pasi A Jänne; Daniel B Costa; Marileila Varella-Garcia; Woo-Ho Kim; Thomas J Lynch; Panos Fidias; Hannah Stubbs; Jeffrey A Engelman; Lecia V Sequist; WeiWei Tan; Leena Gandhi; Mari Mino-Kenudson; Greg C Wei; S Martin Shreeve; Mark J Ratain; Jeffrey Settleman; James G Christensen; Daniel A Haber; Keith Wilner; Ravi Salgia; Geoffrey I Shapiro; Jeffrey W Clark; A John Iafrate
Journal:  N Engl J Med       Date:  2010-10-28       Impact factor: 91.245

3.  Perspectives on the development of imatinib and the future of cancer research.

Authors:  Brian J Druker
Journal:  Nat Med       Date:  2009-10       Impact factor: 53.440

4.  A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.

Authors:  King Pan Ng; Axel M Hillmer; Charles T H Chuah; Wen Chun Juan; Tun Kiat Ko; Audrey S M Teo; Pramila N Ariyaratne; Naoto Takahashi; Kenichi Sawada; Yao Fei; Sheila Soh; Wah Heng Lee; John W J Huang; John C Allen; Xing Yi Woo; Niranjan Nagarajan; Vikrant Kumar; Anbupalam Thalamuthu; Wan Ting Poh; Ai Leen Ang; Hae Tha Mya; Gee Fung How; Li Yi Yang; Liang Piu Koh; Balram Chowbay; Chia-Tien Chang; Veera S Nadarajan; Wee Joo Chng; Hein Than; Lay Cheng Lim; Yeow Tee Goh; Shenli Zhang; Dianne Poh; Patrick Tan; Ju-Ee Seet; Mei-Kim Ang; Noan-Minh Chau; Quan-Sing Ng; Daniel S W Tan; Manabu Soda; Kazutoshi Isobe; Markus M Nöthen; Tien Y Wong; Atif Shahab; Xiaoan Ruan; Valère Cacheux-Rataboul; Wing-Kin Sung; Eng Huat Tan; Yasushi Yatabe; Hiroyuki Mano; Ross A Soo; Tan Min Chin; Wan-Teck Lim; Yijun Ruan; S Tiong Ong
Journal:  Nat Med       Date:  2012-03-18       Impact factor: 53.440

5.  Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer.

Authors:  Sei Hoon Yang; Leah E Mechanic; Ping Yang; Maria Teresa Landi; Elise D Bowman; Jason Wampfler; Daoud Meerzaman; Kyeong Man Hong; Felicia Mann; Tatiana Dracheva; Junya Fukuoka; William Travis; Neil E Caporaso; Curtis C Harris; Jin Jen
Journal:  Clin Cancer Res       Date:  2005-03-15       Impact factor: 12.531

6.  Adjuvant trastuzumab in HER2-positive breast cancer.

Authors:  Dennis Slamon; Wolfgang Eiermann; Nicholas Robert; Tadeusz Pienkowski; Miguel Martin; Michael Press; John Mackey; John Glaspy; Arlene Chan; Marek Pawlicki; Tamas Pinter; Vicente Valero; Mei-Ching Liu; Guido Sauter; Gunter von Minckwitz; Frances Visco; Valerie Bee; Marc Buyse; Belguendouz Bendahmane; Isabelle Tabah-Fisch; Mary-Ann Lindsay; Alessandro Riva; John Crown
Journal:  N Engl J Med       Date:  2011-10-06       Impact factor: 91.245

Review 7.  Predicting response to EGFR inhibitors in metastatic colorectal cancer: current practice and future directions.

Authors:  Veena Shankaran; Jennifer Obel; Al B Benson
Journal:  Oncologist       Date:  2010-02-04

8.  KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

Authors:  Astrid Lièvre; Jean-Baptiste Bachet; Delphine Le Corre; Valérie Boige; Bruno Landi; Jean-François Emile; Jean-François Côté; Gorana Tomasic; Christophe Penna; Michel Ducreux; Philippe Rougier; Frédérique Penault-Llorca; Pierre Laurent-Puig
Journal:  Cancer Res       Date:  2006-04-15       Impact factor: 12.701

Review 9.  East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians.

Authors:  Wei Zhou; David C Christiani
Journal:  Chin J Cancer       Date:  2011-05
  9 in total
  4 in total

1.  Personalized cancer medicine: are we there yet?

Authors:  Mark Lawler; Peter Selby
Journal:  Oncologist       Date:  2013-06

2.  Influence of genetic polymorphisms in glutathione-S-transferases gene in response to imatinib among Brazilian patients with chronic myeloid leukemia.

Authors:  Kezia Aguiar Delmond; Hugo Delleon; Rebeca Mota Goveia; Thallita Monteiro Teixeira; Davi Carvalho Abreu; Francyelli Mello-Andrade; Angela Adamski da Silva Reis; Daniela de Melo E Silva; Adriana do Prado Barbosa; Renato Sampaio Tavares; Carlos Eduardo Anunciação; Elisângela Silveira-Lacerda
Journal:  Mol Biol Rep       Date:  2021-03-11       Impact factor: 2.316

3.  The fourth annual BRDS on genome editing and silencing for precision medicines.

Authors:  Amit Kumar Chaudhary; Rajan Sharma Bhattarai; Ram I Mahato
Journal:  Drug Deliv Transl Res       Date:  2018-02       Impact factor: 4.617

4.  Digital Technology in Somatic and Gene Therapy Trials of Pediatric Patients With Ocular Diseases: Protocol for a Scoping Review.

Authors:  Edward Meinert; Abrar Alturkistani; Tasnime Osama; Celine-Lea Halioua-Haubold; Josip Car; Azeem Majeed; Glenn Wells; Robert E MacLaren; David Brindley
Journal:  JMIR Res Protoc       Date:  2019-02-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.